Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model

Gerlier L, Lamotte M, Greneche S, Lenne X, Carrat F, Weil-Olivier C, Damm O, Schwehm M, Eichner M (2017)
APPLIED HEALTH ECONOMICS AND HEALTH POLICY 15(2): 261-276.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ; ; ; ; ; ; ;
Abstract / Bemerkung
Objectives We estimated the epidemiological and economic impact of extending the French influenza vaccination programme from at-risk/elderly (>= 65 years) only to healthy children (2-17 years). Methods A deterministic, age-structured, dynamic transmission model was used to simulate the transmission of influenza in the French population, using the current vaccination coverage with trivalent inactivated vaccine (TIV) in at-risk/elderly individuals (current strategy) or gradually extending the vaccination to healthy children (aged 2-17 years) with intranasal, quadrivalent live-attenuated influenza vaccine (QLAIV) from current uptake up to 50% (evaluated strategy). Epidemiological, medical resource use and cost data were taken from international literature and country-specific information. The model was calibrated to the observed numbers of influenza-like illness visits/year. The 10-year number of symptomatic cases of confirmed influenza and direct medical costs ('all-payer') were calculated for the 0-17-(direct and indirect effects) and >= 18-year-old (indirect effect). The incremental cost-effectiveness ratio (ICER) was calculated for the total population, using a 4% discount rate/year. Results Assuming 2.3 million visits/year and 1960 deaths/year, the model calibration yielded an all-year average basic reproduction number (R-0) of 1.27. In the population aged 0-17 years, QLAIV prevented 865,000 influenza cases/year (58.4%), preventing 10-year direct medical expenses of (sic)374 million. In those aged >= 18 years with unchanged TIV coverage, 1.2 million cases/year were averted (27.6%) via indirect effects (additionally prevented expenses, (sic)457 million). On average, 613 influenza-related deaths were averted annually overall. The ICER was (sic)18,001/life-year gained. The evaluated strategy had a 98% probability of being cost-effective at a (sic)31,000/life-year gained threshold. Conclusions The model demonstrated strong direct and indirect benefits of protecting healthy children against influenza with QLAIV on public health and economic outcomes in France.
Erscheinungsjahr
Zeitschriftentitel
APPLIED HEALTH ECONOMICS AND HEALTH POLICY
Band
15
Zeitschriftennummer
2
Seite
261-276
ISSN
eISSN
PUB-ID

Zitieren

Gerlier L, Lamotte M, Greneche S, et al. Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model. APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 2017;15(2):261-276.
Gerlier, L., Lamotte, M., Greneche, S., Lenne, X., Carrat, F., Weil-Olivier, C., Damm, O., et al. (2017). Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 15(2), 261-276. doi:10.1007/s40258-016-0296-4
Gerlier, L., Lamotte, M., Greneche, S., Lenne, X., Carrat, F., Weil-Olivier, C., Damm, O., Schwehm, M., and Eichner, M. (2017). Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model. APPLIED HEALTH ECONOMICS AND HEALTH POLICY 15, 261-276.
Gerlier, L., et al., 2017. Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 15(2), p 261-276.
L. Gerlier, et al., “Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model”, APPLIED HEALTH ECONOMICS AND HEALTH POLICY, vol. 15, 2017, pp. 261-276.
Gerlier, L., Lamotte, M., Greneche, S., Lenne, X., Carrat, F., Weil-Olivier, C., Damm, O., Schwehm, M., Eichner, M.: Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model. APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 15, 261-276 (2017).
Gerlier, L., Lamotte, M., Greneche, S., Lenne, X., Carrat, F., Weil-Olivier, C., Damm, Oliver, Schwehm, M., and Eichner, M. “Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model”. APPLIED HEALTH ECONOMICS AND HEALTH POLICY 15.2 (2017): 261-276.

1 Zitation in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016.
Visseaux B, Burdet C, Voiriot G, Lescure FX, Chougar T, Brugière O, Crestani B, Casalino E, Charpentier C, Descamps D, Timsit JF, Yazdanpanah Y, Houhou-Fidouh N., PLoS One 12(7), 2017
PMID: 28708843

50 References

Daten bereitgestellt von Europe PubMed Central.

Influenza-associated pediatric deaths in the United States, 2004-2012.
Wong KK, Jain S, Blanton L, Dhara R, Brammer L, Fry AM, Finelli L., Pediatrics 132(5), 2013
PMID: 24167165

AUTHOR UNKNOWN, 0
Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--5.
Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, Brisson M; ISPOR-SMDM Modeling Good Research Practices Task Force., Value Health 15(6), 2012
PMID: 22999132
Population-wide benefits of routine vaccination of children against influenza.
Weycker D, Edelsberg J, Halloran ME, Longini IM Jr, Nizam A, Ciuryla V, Oster G., Vaccine 23(10), 2005
PMID: 15652671
Estimating the impact of childhood influenza vaccination programmes in England and Wales.
Vynnycky E, Pitman R, Siddiqui R, Gay N, Edmunds WJ., Vaccine 26(41), 2008
PMID: 18647634
Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study.
Baguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJ., PLoS Med. 10(10), 2013
PMID: 24115913
Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005-2011.
Kostova D, Reed C, Finelli L, Cheng PY, Gargiullo PM, Shay DK, Singleton JA, Meltzer MI, Lu PJ, Bresee JS., PLoS ONE 8(6), 2013
PMID: 23840439
The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study.
Rose MA, Damm O, Greiner W, Knuf M, Wutzler P, Liese JG, Kruger H, Wahn U, Schaberg T, Schwehm M, Kochmann TF, Eichner M., BMC Infect. Dis. 14(), 2014
PMID: 24450996
Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany.
Damm O, Eichner M, Rose MA, Knuf M, Wutzler P, Liese JG, Kruger H, Greiner W., Eur J Health Econ 16(5), 2014
PMID: 24859492

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0
Social contacts and mixing patterns relevant to the spread of infectious diseases.
Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, Massari M, Salmaso S, Tomba GS, Wallinga J, Heijne J, Sadkowska-Todys M, Rosinska M, Edmunds WJ., PLoS Med. 5(3), 2008
PMID: 18366252
Time lines of infection and disease in human influenza: a review of volunteer challenge studies.
Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, Valleron AJ., Am. J. Epidemiol. 167(7), 2008
PMID: 18230677
Oral oseltamivir treatment of influenza in children.
Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG, Ward P., Pediatr. Infect. Dis. J. 20(2), 2001
PMID: 11224828
Burden of influenza in children in the community.
Heikkinen T, Silvennoinen H, Peltola V, Ziegler T, Vainionpaa R, Vuorinen T, Kainulainen L, Puhakka T, Jartti T, Toikka P, Lehtinen P, Routi T, Juven T., J. Infect. Dis. 190(8), 2004
PMID: 15378427
[Vaccination against seasonal influenza in France in 2010 and 2011: decrease of coverage rates and associated factors].
Tuppin P, Choukroun S, Samson S, Weill A, Ricordeau P, Allemand H., Presse Med 41(11), 2012
PMID: 22795870

AUTHOR UNKNOWN, 0
Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials.
Rhorer J, Ambrose CS, Dickinson S, Hamilton H, Oleka NA, Malinoski FJ, Wittes J., Vaccine 27(7), 2008
PMID: 19095024
Vaccines for preventing influenza in healthy children.
Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V., Cochrane Database Syst Rev (2), 2008
PMID: 18425905
Comparative efficacy of inactivated and live attenuated influenza vaccines.
Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, Rotthoff J, Boulton M, Victor JC., N. Engl. J. Med. 361(13), 2009
PMID: 19776407
Vaccines for preventing influenza in the elderly.
Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE., Cochrane Database Syst Rev (2), 2010
PMID: 20166072
Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia.
Tam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM, Lee BW, Qian Y, Samakoses R, Lolekha S, Rajamohanan KP, Narayanan SN, Kirubakaran C, Rappaport R, Razmpour A, Gruber WC, Forrest BD; Pan-Asian CAIV-T Pediatric Efficacy Trial Network., Pediatr. Infect. Dis. J. 26(7), 2007
PMID: 17596805

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0
Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium.
Gerlier L, Lamotte M, Dos Santos Mendes S, Damm O, Schwehm M, Eichner M., Paediatr Drugs 18(4), 2016
PMID: 27272706
Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia.
Mauskopf JA, Cates SC, Griffin AD, Neighbors DM, Lamb SC, Rutherford C., Pharmacoeconomics 17(6), 2000
PMID: 10977398
Evaluation of targeted influenza vaccination strategies via population modeling.
Glasser J, Taneri D, Feng Z, Chuang JH, Tull P, Thompson W, Mason McCauley M, Alexander J., PLoS ONE 5(9), 2010
PMID: 20862297

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0
Tecumseh study of illness. XIII. Influenza infection and disease, 1976-1981.
Monto AS, Koopman JS, Longini IM Jr., Am. J. Epidemiol. 121(6), 1985
PMID: 4014174
The impact of illness on social networks: implications for transmission and control of influenza.
Van Kerckhove K, Hens N, Edmunds WJ, Eames KT., Am. J. Epidemiol. 178(11), 2013
PMID: 24100954
The French Connection: The First Large Population-Based Contact Survey in France Relevant for the Spread of Infectious Diseases.
Beraud G, Kazmercziak S, Beutels P, Levy-Bruhl D, Lenne X, Mielcarek N, Yazdanpanah Y, Boelle PY, Hens N, Dervaux B., PLoS ONE 10(7), 2015
PMID: 26176549
Oil-in-water emulsion adjuvant with influenza vaccine in young children.
Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, Baehner F, Borkowski A, Tsai TF, Clemens R., N. Engl. J. Med. 365(15), 2011
PMID: 21995388
Influenza burden of illness: estimates from a national prospective survey of household contacts in France.
Carrat F, Sahler C, Rogez S, Leruez-Ville M, Freymuth F, Le Gales C, Bungener M, Housset B, Nicolas M, Rouzioux C., Arch. Intern. Med. 162(16), 2002
PMID: 12196082

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0
Management of influenza-like illness by homeopathic and allopathic general practitioners in France during the 2009-2010 influenza season.
Vincent S, Demonceaux A, Deswarte D, Scimeca D, Bordet MF., J Altern Complement Med 19(2), 2012
PMID: 22803696
Hospitalization of influenza-like illness patients recommended by general practitioners in France between 1997 and 2010.
Pelat C, Lasserre A, Xavier A, Turbelin C, Blanchon T, Hanslik T., Influenza Other Respir Viruses 7(1), 2012
PMID: 22443191
Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom.
Meier CR, Napalkov PN, Wegmuller Y, Jefferson T, Jick H., Eur. J. Clin. Microbiol. Infect. Dis. 19(11), 2000
PMID: 11152308

AUTHOR UNKNOWN, 0

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 27943165
PubMed | Europe PMC

Suchen in

Google Scholar